Condition: Metastatic Breast Cancer · Sponsor: Lund University Hospital
Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure. The main aim is to develop and validate prognostic, predictive and pathogenic markers in clinically well-characterized population-based material of breast cancer tumors and the corresponding normal tissue.These data will be used to characterize recurrent breast cancer on a molecular level, study tumor evolution, develop biomarkers of response/resistance to targeted therapy in the metastatic setting, enroll patients on targeted treatment clinical studies and to elucidate mechanisms of resistance to therapy.
This description comes directly from the study's public registry record.
Karolina Holm, PhD · +46 730 84 17 61 · karolina.holm@med.lu.se
Christel Reutersward, MSc · christel.reutersward@med.lu.se
Always discuss trial participation with your own doctor first.
| Lund University Hospital | Lund, Sweden | Recruiting |
| Lund University Hospital | Lund, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03758976